These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

633 related articles for article (PubMed ID: 29470805)

  • 61. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings.
    Abdel-Fatah TM; Perry C; Dickinson P; Ball G; Moseley P; Madhusudan S; Ellis IO; Chan SY
    Ann Oncol; 2013 Nov; 24(11):2801-7. PubMed ID: 23908177
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
    Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
    Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Circulating immune cell dynamics in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.
    Talamantes S; Xie E; Costa RLB; Chen M; Rademaker A; Santa-Maria CA
    Cancer Med; 2020 Oct; 9(19):6954-6960. PubMed ID: 32757467
    [TBL] [Abstract][Full Text] [Related]  

  • 64. BRCAness digitalMLPA profiling predicts benefit of intensified platinum-based chemotherapy in triple-negative and luminal-type breast cancer.
    Lips EH; Benard-Slagter A; Opdam M; Scheerman CE; Wesseling J; Hogervorst FBL; Linn SC; Savola S; Nederlof PM
    Breast Cancer Res; 2020 Jul; 22(1):79. PubMed ID: 32711554
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.
    Fourquet A; Stoppa-Lyonnet D; Kirova YM; Sigal-Zafrani B; Asselain B; ;
    Am J Clin Oncol; 2009 Apr; 32(2):127-31. PubMed ID: 19307946
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
    Gass P; Lux MP; Rauh C; Hein A; Bani MR; Fiessler C; Hartmann A; Häberle L; Pretscher J; Erber R; Wachter DL; Schulz-Wendtland R; Beckmann MW; Fasching PA; Wunderle M
    BMC Cancer; 2018 Oct; 18(1):1051. PubMed ID: 30373556
    [TBL] [Abstract][Full Text] [Related]  

  • 67. TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.
    Isakoff SJ; Mayer EL; He L; Traina TA; Carey LA; Krag KJ; Rugo HS; Liu MC; Stearns V; Come SE; Timms KM; Hartman AR; Borger DR; Finkelstein DM; Garber JE; Ryan PD; Winer EP; Goss PE; Ellisen LW
    J Clin Oncol; 2015 Jun; 33(17):1902-9. PubMed ID: 25847936
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Advances in the systemic treatment of triple-negative breast cancer.
    Lebert JM; Lester R; Powell E; Seal M; McCarthy J
    Curr Oncol; 2018 Jun; 25(Suppl 1):S142-S150. PubMed ID: 29910657
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
    Kim R; Osaki A; Tanabe K; Toge T
    Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer.
    Villarreal-Garza C; Weitzel JN; Llacuachaqui M; Sifuentes E; Magallanes-Hoyos MC; Gallardo L; Alvarez-Gómez RM; Herzog J; Castillo D; Royer R; Akbari M; Lara-Medina F; Herrera LA; Mohar A; Narod SA
    Breast Cancer Res Treat; 2015 Apr; 150(2):389-94. PubMed ID: 25716084
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
    Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
    J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer.
    Lien MY; Liu LC; Wang HC; Yeh MH; Chen CJ; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Li LY; Lin PH; Chiu CF
    Anticancer Res; 2014 Dec; 34(12):7319-26. PubMed ID: 25503167
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy.
    Li J; Chen S; Chen C; Di G; Liu G; Wu J; Shao Z
    Oncotarget; 2017 Mar; 8(11):18399-18408. PubMed ID: 27191991
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Analysis of the relevance between molecular subtypes and efficacy of neoadjuvant chemotherapy in breast cancer as well as its prognostic factors.
    Li F; Ma L; Geng C; Liu C; Deng H; Yue M; Ding Y; Wang X; Liu Y
    Pathol Res Pract; 2018 Aug; 214(8):1166-1172. PubMed ID: 29945816
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers.
    Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    Cancer Sci; 2018 Jan; 109(1):166-173. PubMed ID: 29047188
    [TBL] [Abstract][Full Text] [Related]  

  • 76. p53 alteration in morphologically normal/benign breast luminal cells in BRCA carriers with or without history of breast cancer.
    Wang X; El-Halaby AA; Zhang H; Yang Q; Laughlin TS; Rothberg PG; Skinner K; Hicks DG
    Hum Pathol; 2017 Oct; 68():22-25. PubMed ID: 28438622
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer.
    Kurian AW; Ward KC; Abrahamse P; Hamilton AS; Deapen D; Morrow M; Jagsi R; Katz SJ
    JAMA Oncol; 2020 Apr; 6(4):e196400. PubMed ID: 32027353
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Altered glycometabolism affects both clinical features and prognosis of triple-negative and neoadjuvant chemotherapy-treated breast cancer.
    Dong T; Kang X; Liu Z; Zhao S; Ma W; Xuan Q; Liu H; Wang Z; Zhang Q
    Tumour Biol; 2016 Jun; 37(6):8159-68. PubMed ID: 26715276
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical outcomes of adjuvant taxane plus anthracycline versus taxane-based chemotherapy regimens in older adults with node-positive, triple-negative breast cancer: A SEER-Medicare study.
    Roy S; Lakritz S; Schreiber AR; Molina E; Kabos P; Wood M; Elias A; Kondapalli L; Bradley CJ; Diamond JR
    Eur J Cancer; 2023 May; 185():69-82. PubMed ID: 36965330
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kriege M; Seynaeve C; Meijers-Heijboer H; Collee JM; Menke-Pluymers MB; Bartels CC; Tilanus-Linthorst MM; Blom J; Huijskens E; Jager A; van den Ouweland A; van Geel B; Hooning MJ; Brekelmans CT; Klijn JG
    J Clin Oncol; 2009 Aug; 27(23):3764-71. PubMed ID: 19564533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.